Want to see ACAD full AI Analyst Report?
ACAD Stock Chart & Stats
$22.17
-$0.09(-0.52%)
At close: 4:00 PM EST
$22.17
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$19.69 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.52M
Market Cap
$4.45B
Enterprise Value$3.47B
Total Cash (Recent Filing)$851.46M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)11.8
Beta1.07
Next Earnings
Aug 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding171,235,870
10 Day Avg. Volume2,000,206
30 Day Avg. Volume1,521,872
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda27.32
Forecast
1Y Price Target
$32.21Price Target Upside45.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.38
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Conservative, Low‑leverage Balance SheetSustained low leverage and a stronger equity base give ACADIA durable financial flexibility to fund commercial rollouts and multiple clinical programs without urgent external financing. This reduces refinancing risk, supports continued R&D investment, and improves resilience to biotech cycle volatility.
Commercial Momentum For Core ProductsGrowing sales across NUPLAZID and DAYBUE, early uptake of the STIX formulation, and a 30% salesforce expansion indicate a scalable commercial model. If uptake continues, fixed commercial investments should leverage revenue growth, supporting stable long‑term top‑line expansion and payor access.
Near‑term Pipeline Catalysts And DiversificationMultiple upcoming clinical readouts and a diversified pipeline targeting large CNS indications materially increase the chance of new revenue streams. Positive outcomes would de‑risk reliance on current products, extend the commercial runway, and materially raise long‑term growth potential.
Bears Say
Large SG&A Increase Pressures ProfitabilityA sustained ~35% step‑up in commercial spend materially increases fixed costs and requires durable revenue gains to maintain margins. If sales acceleration is slower than assumed, operating leverage works against profitability and cash flow, raising execution risk over the next 2–6 months and beyond.
High Gross‑to‑net Deductions Reduce Net RevenueElevated gross‑to‑net deductions meaningfully erode topline realized revenue despite unit demand. Persistent high deductions compress margins, complicate forecasting and cash conversion, and limit the benefit of nominal sales growth unless payor and rebate dynamics improve structurally.
Regulatory Uncertainty For Trofinetide In EuropeOngoing reexamination in Europe creates a meaningful execution risk for international expansion. A delayed or adverse outcome would slow market diversification, reduce projected peak sales from the candidate, and force reliance on U.S. markets or additional trials, raising development cost and timeline uncertainty.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest stock price was $19.69 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $4.45B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 32 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on May 06, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.051 by -$0.031.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.02 in its last earnings report, missing expectations of $0.051. Following the earnings report the stock price went up 5.028%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.21 (45.31% Upside)
$32.21 (45.31% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 784.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.69%
12-Months-Change
Fundamentals
Return on Equity
35.65%
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial and pipeline picture: solid Q1 revenue growth (+11% adjusted), robust DAYBUE momentum (+20% YoY) and encouraging early uptake of the DAYBUE STIX formulation, continued demand and referral gains for NUPLAZID, a strong cash position ($851M) and major near‑term clinical catalysts (remlifanserin Phase II readout and trofinetide Japan Phase III). Headwinds include a temporary refill timing disruption that impacted Q1 NUPLAZID revenue timing, a sizable near‑term increase in SG&A (+35.3% YoY) to fund commercial expansion, ongoing regulatory uncertainty in Europe for trofinetide, and an R&D leadership transition. On balance, the positives (top‑line growth, product launches, reaffirmed guidance, pipeline catalysts and healthy cash) outweigh the challenges, which management describes largely as temporary or strategic investments.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$32.21
▲(45.31% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
23.27% Insiders
16.14% Mutual Funds
0.10% Other Institutional Investors
37.30% Public Companies and
Individual Investors